MACI or knee replacement for younger patientsYoung patients accepting total knee replacement face a 35% lifetime probability of revision surgery; MACI cartilage repair preserves the native knee in nine out of ten well-selected cases over ten years.Young patients accepting total knee replacement face a 35% lifetime probability of revision surgery; MACI cartilage repair preserves the native knee in nine out of ten well-selected cases over ten years.
ChondroFiller injection side effects and safetyOver 19,000 ChondroFiller cases since 2013 have recorded zero serious adverse device effects and a 0.06% complaint rate, though the evidence derives largely from manufacturer post-market surveillance rather than large independent trials.Over 19,000 ChondroFiller cases since 2013 have recorded zero serious adverse device effects and a 0.06% complaint rate, though the evidence derives largely from manufacturer post-market surveillance rather than large independent trials.
When shoulder impingement needs a specialist assessmentArthroscopic shoulder surgery produces no clinically meaningful benefit over physiotherapy, according to landmark trials—yet one-third of patients proceed to surgery without attempting conservative care first.Arthroscopic shoulder surgery produces no clinically meaningful benefit over physiotherapy, according to landmark trials—yet one-third of patients proceed to surgery without attempting conservative care first.
ChondroFiller or Arthrosamid for knee cartilageChondroFiller and Arthrosamid are not interchangeable fillers — they address different anatomical targets within the knee. ChondroFiller is a collagen scaffold placed directly on the cartilage surface to recruit the patient's own repair cells; Arthrosamid is a permanent hydrogel in the synovial lining that provides mechanical cushioning.ChondroFiller and Arthrosamid are not interchangeable fillers — they address different anatomical targets within the knee. ChondroFiller is a collagen scaffold placed directly on the cartilage surface to recruit the patient's own repair cells; Arthrosamid is a permanent hydrogel in the synovial lining that provides mechanical cushioning.
When ankle sprain needs more than A&EA&E correctly rules out fractures but cannot assess ligament damage; most ankle sprain patients leave with rest-ice advice alone, yet structured physiotherapy reduces 12-month re-injury rates by roughly 40 per cent compared with routine care.A&E correctly rules out fractures but cannot assess ligament damage; most ankle sprain patients leave with rest-ice advice alone, yet structured physiotherapy reduces 12-month re-injury rates by roughly 40 per cent compared with routine care.
Ultrasound-guided ChondroFiller injection for hip cartilage defectsChondroFiller is an acellular collagen scaffold that recruits the patient's own cells to repair focal hip cartilage defects. Treatment works best for Grade III–IV lesions greater than 2 cm² in Tönnis Grade 0–1 joints.ChondroFiller is an acellular collagen scaffold that recruits the patient's own cells to repair focal hip cartilage defects. Treatment works best for Grade III–IV lesions greater than 2 cm² in Tönnis Grade 0–1 joints.
Which specialist treats supraspinatus tendinopathySupraspinatus tendinopathy is not a single diagnosis; the term covers three distinct conditions—tendinitis, tendinosis, and partial tears—each requiring different treatment, managed sequentially by physiotherapists and then specialists depending on rehabilitation progress.Supraspinatus tendinopathy is not a single diagnosis; the term covers three distinct conditions—tendinitis, tendinosis, and partial tears—each requiring different treatment, managed sequentially by physiotherapists and then specialists depending on rehabilitation progress.
What IKDC and MOCART data show about ChondroFillerChondroFiller injection improves knee function by an average of 30 points on the IKDC scale — double the clinically meaningful threshold — across independent studies, though evidence derives from small cohorts of younger patients with focal cartilage defects.ChondroFiller injection improves knee function by an average of 30 points on the IKDC scale — double the clinically meaningful threshold — across independent studies, though evidence derives from small cohorts of younger patients with focal cartilage defects.
Who to see first for back pain and sciaticaUp to 90% of sciatica cases resolve without surgery within weeks to months, and the evidence points to starting with physiotherapy, not a pain consultant or surgeon.Up to 90% of sciatica cases resolve without surgery within weeks to months, and the evidence points to starting with physiotherapy, not a pain consultant or surgeon.
Questions to ask before a ChondroFiller injectionChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.ChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.
Knee cartilage damage symptoms and who to seeArticular cartilage lacks a blood supply and cannot repair itself; untreated defects larger than 1 cm risk progressive worsening and osteoarthritis.Articular cartilage lacks a blood supply and cannot repair itself; untreated defects larger than 1 cm risk progressive worsening and osteoarthritis.
ChondroFiller repeat injections and long-term repairChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.ChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.